Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030486077> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3030486077 endingPage "253" @default.
- W3030486077 startingPage "249" @default.
- W3030486077 abstract "Objective To investigate the growth inhibition and radiosensitization of Celecoxib in hu-man nasopharyngeal carcinoma cell line CNE-2. Methods CNE-2 growth inhibition by Celecoxib was eval-uated by MTT method. Apoptosis-related changes in morphology were observed by transmission electron mi-croscopy (TEM). Cell cycle distribution and apoptosis rate were measured by flowcytometry (FCM). The ex-pression of COX-2 protein was observed by SP method after the treatment of Celecoxib. Cells were randomly planted into four groups: irradiation control(Ci), drug group(Cd), irradiation group(R), and Celecoxib plus irradiation group(D+R). Single irradiation of 2,4,6,8,and 10 Gy were administered for colonogenic assay. Cell cycle distribution and apoptosis rate were analyzed at 6 Gy irradiation. Results The growth of CNE-2 cell was inhibited by celecoxib in a dose-and time-dependent manner, the IC50 was 80 μmol/L After the treatment, cell ratio of GO and G, phases was increased (47.03±2.76 vs 56.17±1.95, t=4.68, P= 0.010), whereas the ratio of S and G2/M phases was decreased (33.07±1.86 vs 24.87±1.76, t=5.54, P = 0.010; 19.30±0.53: 17.73±0.83, t=2.75, P=0.050), and the apoptosis rate was increased (1.57±0.47:10.47±0.31, t = 27.39, P = 0.000) in a dose-dependent manner. Apoptosis with nuclear chromatin condensation, fragmentation and cell shrinkage was found by TEM. SP method showed that Celeib decreased COX-2 expression (17.48±0.34 vs 12.82±0.51,t=13.20,P =0.00). The sensitivity ratio(D0) was 1.15. FCM showed that the percentage of cells in G2/M phase was significanty more in R and D+R groups than in Ci and Cd groups (68.00±1.65,54.27±5.74,17.60±0.80,14.86±1.23, t=47.70,P=0.000; t=11.63, P=0.000), and also significantly different between R group and D + R group (t=3.99, P= 0.020). The apoptosis rate was higher in R and D + R groups than Ci and Cd groups(4.83±0.97,9.50± 1.35,1.33±0.86 and 2.28±0.42,t=4.67,P=0.010;t=8.81, P=0.000), D + R group than R group(t =4.85,P=0.010). Conclusions Celecoxib can markedly inhibit the growth and induce apoptosis in CNE-2 cells,which may depend on COX-2 pathway. Celeeoxib potently enhances the radiosensitivity of CNE-2 cells,which may due to the repair inhibit of radiation-induced DNA damage, inhibit of cell proliferation,and enhancement of cell apoptosis after irradiation.Key words: Cell line,nasopharyngeal neoplasms/human; Celecoxib; Cell proliferation; Cell apoptosis; Radiosensitization" @default.
- W3030486077 created "2020-06-05" @default.
- W3030486077 creator A5008199212 @default.
- W3030486077 creator A5008881767 @default.
- W3030486077 creator A5011805077 @default.
- W3030486077 creator A5034539485 @default.
- W3030486077 date "2009-05-15" @default.
- W3030486077 modified "2023-09-23" @default.
- W3030486077 title "Growth inhibition and radiosensitization of Celecoxib in nasopharyngeal carcinoma cell line CNE-2" @default.
- W3030486077 doi "https://doi.org/10.3760/cma.j.issn.1004-4221.2009.03.249" @default.
- W3030486077 hasPublicationYear "2009" @default.
- W3030486077 type Work @default.
- W3030486077 sameAs 3030486077 @default.
- W3030486077 citedByCount "0" @default.
- W3030486077 crossrefType "journal-article" @default.
- W3030486077 hasAuthorship W3030486077A5008199212 @default.
- W3030486077 hasAuthorship W3030486077A5008881767 @default.
- W3030486077 hasAuthorship W3030486077A5011805077 @default.
- W3030486077 hasAuthorship W3030486077A5034539485 @default.
- W3030486077 hasConcept C126322002 @default.
- W3030486077 hasConcept C1491633281 @default.
- W3030486077 hasConcept C153911025 @default.
- W3030486077 hasConcept C185592680 @default.
- W3030486077 hasConcept C18903297 @default.
- W3030486077 hasConcept C190283241 @default.
- W3030486077 hasConcept C191015642 @default.
- W3030486077 hasConcept C202751555 @default.
- W3030486077 hasConcept C2776467144 @default.
- W3030486077 hasConcept C2777752497 @default.
- W3030486077 hasConcept C2778997737 @default.
- W3030486077 hasConcept C2779707156 @default.
- W3030486077 hasConcept C29537977 @default.
- W3030486077 hasConcept C509974204 @default.
- W3030486077 hasConcept C54355233 @default.
- W3030486077 hasConcept C55493867 @default.
- W3030486077 hasConcept C62112901 @default.
- W3030486077 hasConcept C71924100 @default.
- W3030486077 hasConcept C81885089 @default.
- W3030486077 hasConcept C86803240 @default.
- W3030486077 hasConcept C98274493 @default.
- W3030486077 hasConceptScore W3030486077C126322002 @default.
- W3030486077 hasConceptScore W3030486077C1491633281 @default.
- W3030486077 hasConceptScore W3030486077C153911025 @default.
- W3030486077 hasConceptScore W3030486077C185592680 @default.
- W3030486077 hasConceptScore W3030486077C18903297 @default.
- W3030486077 hasConceptScore W3030486077C190283241 @default.
- W3030486077 hasConceptScore W3030486077C191015642 @default.
- W3030486077 hasConceptScore W3030486077C202751555 @default.
- W3030486077 hasConceptScore W3030486077C2776467144 @default.
- W3030486077 hasConceptScore W3030486077C2777752497 @default.
- W3030486077 hasConceptScore W3030486077C2778997737 @default.
- W3030486077 hasConceptScore W3030486077C2779707156 @default.
- W3030486077 hasConceptScore W3030486077C29537977 @default.
- W3030486077 hasConceptScore W3030486077C509974204 @default.
- W3030486077 hasConceptScore W3030486077C54355233 @default.
- W3030486077 hasConceptScore W3030486077C55493867 @default.
- W3030486077 hasConceptScore W3030486077C62112901 @default.
- W3030486077 hasConceptScore W3030486077C71924100 @default.
- W3030486077 hasConceptScore W3030486077C81885089 @default.
- W3030486077 hasConceptScore W3030486077C86803240 @default.
- W3030486077 hasConceptScore W3030486077C98274493 @default.
- W3030486077 hasIssue "03" @default.
- W3030486077 hasLocation W30304860771 @default.
- W3030486077 hasOpenAccess W3030486077 @default.
- W3030486077 hasPrimaryLocation W30304860771 @default.
- W3030486077 hasRelatedWork W2352703463 @default.
- W3030486077 hasRelatedWork W2354720491 @default.
- W3030486077 hasRelatedWork W2355095594 @default.
- W3030486077 hasRelatedWork W2357345756 @default.
- W3030486077 hasRelatedWork W2361706675 @default.
- W3030486077 hasRelatedWork W2364981465 @default.
- W3030486077 hasRelatedWork W2368475037 @default.
- W3030486077 hasRelatedWork W2376695291 @default.
- W3030486077 hasRelatedWork W2379872266 @default.
- W3030486077 hasRelatedWork W2385016874 @default.
- W3030486077 hasRelatedWork W2387966668 @default.
- W3030486077 hasRelatedWork W2389718928 @default.
- W3030486077 hasRelatedWork W2399789517 @default.
- W3030486077 hasRelatedWork W2620149588 @default.
- W3030486077 hasRelatedWork W3028791085 @default.
- W3030486077 hasRelatedWork W3029945750 @default.
- W3030486077 hasRelatedWork W3030569982 @default.
- W3030486077 hasRelatedWork W3031724978 @default.
- W3030486077 hasRelatedWork W3031970863 @default.
- W3030486077 hasRelatedWork W3030176935 @default.
- W3030486077 hasVolume "18" @default.
- W3030486077 isParatext "false" @default.
- W3030486077 isRetracted "false" @default.
- W3030486077 magId "3030486077" @default.
- W3030486077 workType "article" @default.